🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Final analysis of MAIA study at ~7.5 yr f/up: 33% reduction in risk of death with Dara in treatment ineligible NDMM Hang Quach #Blood2024

Listen to our latest episode of Blood Cancer Talks to learn about the latest data on belantamab in #Myeloma! Also, Hang Quach gave us excellent clinical pearls on management of ocular toxicity. Eddie Cliff Ashwin Kishtagari, MD

#4 Efficacy of a new trispecific antibody in relapsed refractory myeloma: ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific. Hang Quach #ASH24 Immunotherapy has revolutionized myeloma therapy and we have continued progress. ash.confex.com/ash/2024/webpr…

Check out the latest Blood Cancer Talks episode with Raj Chakraborty, Ashwin Kishtagari, MD, and Eddie Cliff! This time, the hosts are joined by Hang Quach, of @StVincentsMelb, for a discussion on belantamab mafodotin in multiple #myeloma. 🎧 Listen here! buff.ly/4g1Jryd

#ASH24WarmUp Looking forward to moderating this session at #ASH24. Join us for some great oral abstracts (many in top 5 lists) lined up for presentation & discussion on Dec 9!! Joshua Richter, MD, FACP Hang Quach Michael H. Tomasson, MD #mmsm #MedTwitter ASH Myeloma Society

Re-engaging life post BCMA for Myeloma-emerging possibilities are expanding, here at #ASH24. Stay tuned. sciencedirect.com/science/articl…

Interesting and important upcoming results of the trispecific ISB2001 to be presented during #ASH24 . It targets 3 key molecules: 1. CD38 (on myeloma cells) 2. BCMA (also on myeloma cells) 3. CD3 (on T cells) It combines the functions of antibody-dependent cellular

Australian Hang Quach presents first results of Phase 1 dose escalation of ISB 2001, a BCMAxCD38xCD3 targeting trispecific in RRMM at #ASH24. Grade 3/4 infections 15% 83% ORR. 90% in CAR-T/bispecific naive, 86% prior BCMA therapy, 85% CD38 refractory. Dose escalation continues

CONGRESS | #ASH24 | Hang Quach Hang Quach @StVincentsMelb shares the first results of the phase I trial of ISB 2001, a trispecific antibody, for RRMM. DL1-7 ORR 75%, DL3-7 ORR 83%, highest ORR observed in patients naïve to CAR-T and bsAb 90%. No DLTs observed up to 1200µg/kg QW.

#ASCO25 ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for RRMM. N=24, median f/u 6 months, 6 prior lines, CRS 715, No ICANS. ORR: 75% across 8 dose levels meetings.asco.org/abstracts-pres… #mmsm #bmtsm Hang Quach

First interview of #ASCO25 is in the books! Hang Quach of University of Melbourne stopped by to share data from the dose-escalation portion of a first-in-human study of the trispecific antibody ISB 2001 in R/R myeloma! Hear her preview the topline findings below. ASCO #mmsm #oncology

#4 ISB 2001 Trispecific CD3/BCMA/CD38 antibody. #ASCO25 75% response rate in phase I in refractory myeloma Hang Quach meetings.asco.org/abstracts-pres…

CONGRESS | #ASCO25 | POSTER | Hang Quach University of Melbourne presents the efficacy and safety data from the phase II IZALCO study of SC Isa-Kd in R/R #MultipleMyeloma. Results demonstrated the feasibility of SC isatuximab, through either a manual or OBDS administration, with an ORR of

"What makes ISB 2001 unique and distinctly different from other traditional bispecific antibodies is, firstly, the dual and high-affinity binding to CD38 and BCMA," said Hang Quach, MBBS, FRACP, FRCPA, MD (Hang Quach). #ASCO25 | ASCO hubs.li/Q03qbtXr0

CONGRESS | #ASCO25 | Hang Quach University of Melbourne shared the dose-escalation results from the phase I TRIgnite-1 study of ISB 2001 for R/R #MultipleMyeloma. There were no DLT observed up to 2700ug/kg. At active doses ORR 79% with ≥CR 30% and 75% MRD neg rate. Efficacy was observed

CONGRESS | #ASCO25 | Hang Quach University of Melbourne shares initial results from part 1 of the MagnetisMM-6 study of elranatamab + DR for patients with transplant-ineligible newly diagnosed #MultipleMyeloma. Elranatamab 76mg Q4W + standard dose DR demonstrated ORR of 97.3% with a

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma ASCO Hang Quach St Vincent's Melb - Haematology #ASCO25 #mmsm hubs.li/Q03qzDVN0

In our latest Steering Committee meeting, Paul Richardson Dana-Farber chaired a discussion on XPO1 as a target for the treatment of #MultipleMyeloma with a focus on real-world evidence. Watch here: loom.ly/O5Ch65M #mmsm #myeloma #MedEd marivi mateos Hang Quach Morie Gertz

New high risk definition for myeloma is out! Time to start doing TP53 mutation for all myeloma cases. #IMWG ascopubs.org/doi/10.1200/JC…

The Multiple Myeloma Hub was pleased to speak with Hang Quach. We asked, How are BCMA-directed BsAbs currently utilized in real-world practice for #MultipleMyeloma? loom.ly/jhvjkaw #mmsm #myeloma #MedEd Hang Quach University of Melbourne